MONTE ROSA THERAPEUTICS INC (GLUE) Stock Income Statement
USA - NASDAQ:GLUE - US61225M1027 - Common Stock
6.53 USD
+0.2 (+3.16%)
6.53 USD
0 (0%)
| TTM (2025-6-30) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 177.99M | 75.62M | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 163.03M | 156.73M | 143.31M | 112.38M | 72.88M | |||
| Research and Development | 129.32M | 112.86M | 103.37M | 77.26M | 57.16M | |||
| Selling, General, and Administrative Expenses | 33.70M | 43.87M | 39.94M | 35.12M | 15.73M | |||
| Operating Income | 14.96M | -81.11M | -143.31M | -112.38M | -72.88M | |||
| Interest Income/Expense | 13.41M | 10.98M | 8.27M | 3.77M | -120.00K | |||
| Other Income/Expense | N/A | N/A | N/A | 0.00 | -960.00K | |||
| Income Before Taxes | 28.42M | -70.13M | -135.01M | -108.50M | -73.96M | |||
| Income Tax | 4.26M | 2.57M | 338.00K | N/A | N/A | |||
| Net Income | 24.17M | -72.70M | -135.35M | -108.50M | -73.96M | |||
| EBITDA | 23.30M | -72.99M | -137.09M | -108.63M | -70.75M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | 0.29 | -0.98 | -2.63 | -2.30 | -1.59 | |||
| Non GAAP EPS | 0.35 | -1.02 | -2.64 | -2.29 | N/A | |||
| Statistics | ||||||||
| Profit Margin | 13.58% | -96.14% | N/A | N/A | N/A | |||
| Operating Profit Margin | 8.40% | -107.26% | N/A | N/A | N/A | |||
All data in USD